NCT02837107

Brief Summary

While it is well accepted that a low level of RONS production is necessary to maintain physiological function, too much formation of RONS are believed to participate in biomolecules damage. Damage of lipids, proteins and DNA/RNA, to cellular and tissue level, as a consequence of oxidative stress has been linked to a number of serious diseases, including cancer, cardiovascular diseases (CVDs) such as hypertension and atherosclerosis, neurodegenerative diseases such as Parkinson's disease and Alzheimer's dementias, diabetes and the process of aging. The dietary intake of antioxidants is thought to play a major role in oxidative stress network. Many epidemiologic studies have reported an inverse association between vegetable and fruit consumption with reduced risk of chronic diseases, especially cancer and CVDs. However, although many clinical trials have been conducted with vitamins (E, C or their combinations) their in vivo protective effect remains uncertain. Therefore the possibility that the complex mixture of phytochemicals in foods may contribute to their protecting effects has been raised. In this concept, it is possible multiple compounds to act through complimentary or synergistic mechanisms to present a greater biologic effect than can be achieved by any individual component To investigate this hypothesis, a double-blind, randomized, and placebo-controlled clinical trial was conducted in order to investigate the effects of a multi-micronutrient supplement against oxidative stress in apparently healthy adults.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Sep 2013

Longer than P75 for not_applicable healthy

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

May 23, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 19, 2016

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

July 20, 2016

Status Verified

July 1, 2016

Enrollment Period

1.1 years

First QC Date

May 23, 2016

Last Update Submit

July 19, 2016

Conditions

Outcome Measures

Primary Outcomes (14)

  • Change from Baseline of isoprostane levels at 4 weeks

    urinary isoprostane

    0, 4 weeks

  • Change from Baseline of isoprostane levels at 8 weeks

    urinary isoprostane

    0, 8 weeks

  • Change from Baseline of DNA/RNA damage at 4 weeks

    urinary DNA/RNA damage

    0, 4 weeks

  • Change from Baseline of DNA/RNA damage at 8 weeks

    urinary DNA/RNA damage

    0, 8 weeks

  • Change from Baseline of protein carbonyls levels at 4 weeks

    serum

    0, 4 weeks

  • Change from Baseline of protein carbonyls levels at 8 weeks

    serum

    0, 8 weeks

  • Change from Baseline of oxLDL levels at 4 weeks

    serum

    0, 4 weeks

  • Change from Baseline of oxLDL levels at 8 weeks

    serum

    0, 8 weeks

  • Change from Baseline of TBARS levels at 4 weeks

    serum

    0, 4 weeks

  • Change from Baseline of TBARS levels at 8 weeks

    serum

    0, 8 weeks

  • Change from Baseline of serum resistant in oxidation at 4 weeks

    ex vivo serum oxidation with cupper

    0, 4 weeks

  • Change from Baseline of serum resistant in oxidation at 8 weeks

    ex vivo serum oxidation with cupper

    0, 8 weeks

  • Change from Baseline of anti-oxidant enzymes activity at 4 weeks

    serum

    0, 4 weeks

  • Change from Baseline of anti-oxidant enzymes activity at 8 weeks

    serum

    0, 8 weeks

Secondary Outcomes (8)

  • Change from Baseline of Platelet aggregation against PAF at 4 weeks

    0, 4 weeks

  • Change from Baseline of Platelet aggregation against PAF at 8 weeks

    0, 8 weeks

  • Change from Baseline of Platelet aggregation at against ADP 4 weeks

    0, 4 weeks

  • Change from Baseline of Platelet aggregation against ADP at 8 weeks

    0, 8 weeks

  • Change from Baseline of Platelet aggregation against TRAP at 4 weeks

    0, 4 weeks

  • +3 more secondary outcomes

Study Arms (2)

Supplement

ACTIVE COMPARATOR

The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).

Dietary Supplement: Mind Master

Placebo

PLACEBO COMPARATOR

A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.

Dietary Supplement: Placebo

Interventions

Mind MasterDIETARY_SUPPLEMENT

80ml Mind Master / day for 8 weeks

Also known as: Mind Master LR Health & Beauty Systems
Supplement
PlaceboDIETARY_SUPPLEMENT

80ml a look-alike Placebo / day for 8 weeks

Placebo

Eligibility Criteria

Age25 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy
  • BMI: 23-30

You may not qualify if:

  • regular use of dietary supplements or medications
  • being on slimming or any other special diet
  • hypertension
  • metabolic or endocrine disease
  • gastrointestinal disorders
  • recent history of medical or surgical events

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Fragopoulou E, Gavriil L, Argyrou C, Malagaris I, Choleva M, Antonopoulou S, Afxentiou G, Nikolaou E. Suppression of DNA/RNA and protein oxidation by dietary supplement which contains plant extracts and vitamins: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2018 Aug 16;17(1):187. doi: 10.1186/s12944-018-0836-z.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Biological Chemistry

Study Record Dates

First Submitted

May 23, 2016

First Posted

July 19, 2016

Study Start

September 1, 2013

Primary Completion

October 1, 2014

Study Completion

December 1, 2017

Last Updated

July 20, 2016

Record last verified: 2016-07